InvestorsHub Logo
Followers 2
Posts 120
Boards Moderated 0
Alias Born 02/25/2012

Re: BlueGun post# 349

Saturday, 07/12/2014 2:19:07 PM

Saturday, July 12, 2014 2:19:07 PM

Post# of 233477
I agree Nader and the board should be pushing for a sale or at minimum a partnership this year. Obviously, much depends on current sub trial results and if FDA gives their blessing by designating P 140 for orphan or breakthrough status which makes it more appealing to potential suitors. Stock price matters most where we finish not where we are today but there is the problem of cash to continue operations into 2015 if a deal isn't struck hence plan B, reverse split. If sub trial results aren't compelling enough to garner a deal then we are left with Drexel and Dr Jacobson who hasn't even started so looking at min 18 months before he finishes and gets peer reviewed.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News